Show simple item record

Anticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies.

dc.contributor.authorElmaaty, A
dc.contributor.authorEldehna, W
dc.contributor.authorM, Khattab
dc.contributor.authorKutkat, O
dc.contributor.authorAlnajjar, R
dc.contributor.authorEl-Taweel, A
dc.contributor.authorAl-Rashood, S
dc.contributor.authorAbourehab, M
dc.contributor.authorBinjubair, F
dc.contributor.authorSaleh, M
dc.date.accessioned2022-11-08T08:20:01Z
dc.date.available2022-11-08T08:20:01Z
dc.date.issued2022-11-07
dc.identifier.urihttp://repository.limu.edu.ly/handle/123456789/4549
dc.language.isoenen_US
dc.publisherFaculty of Pharmacyen_US
dc.rightsAttribution 3.0 United States*
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/us/*
dc.titleAnticoagulants as Potential SARS-CoV-2 Mpro Inhibitors for COVID-19 Patients: In Vitro, Molecular Docking, Molecular Dynamics, DFT, and SAR Studies.en_US
dc.typeArticleen_US


Files in this item

Thumbnail
Name:
ijms-23-12235-v5.pdf
Size:
24.11Mb
Format:
PDF
Thumbnail
Name:
license_rdf
Size:
913bytes
Format:
application/rdf+xml

This item appears in the following Collection(s)

Show simple item record

Attribution 3.0 United States
Except where otherwise noted, this item's license is described as Attribution 3.0 United States